Corbus Pharmaceuticals Holdings, Inc.
CRBP
$6.68
$0.558.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 42.10M | 32.22M | 30.42M | 26.16M | 23.54M |
| Gross Profit | -42.10M | -32.22M | -30.42M | -26.16M | -23.54M |
| SG&A Expenses | 16.77M | 16.50M | 15.81M | 14.05M | 13.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.87M | 48.72M | 46.22M | 40.20M | 37.40M |
| Operating Income | -58.87M | -48.72M | -46.22M | -40.20M | -37.40M |
| Income Before Tax | -50.29M | -40.21M | -38.70M | -34.97M | -33.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.29 | -40.21 | -38.70 | -34.97 | -33.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.29M | -40.21M | -38.70M | -34.97M | -33.76M |
| EBIT | -58.87M | -48.72M | -46.22M | -40.20M | -37.40M |
| EBITDA | -58.36M | -48.13M | -45.62M | -39.60M | -36.79M |
| EPS Basic | -4.23 | -3.66 | -4.70 | -5.82 | -6.97 |
| Normalized Basic EPS | -2.64 | -2.29 | -2.93 | -3.64 | -4.36 |
| EPS Diluted | -4.23 | -3.66 | -4.70 | -5.82 | -6.97 |
| Normalized Diluted EPS | -2.64 | -2.29 | -2.93 | -3.64 | -4.36 |
| Average Basic Shares Outstanding | 47.45M | 43.56M | 35.80M | 28.21M | 21.44M |
| Average Diluted Shares Outstanding | 47.45M | 43.56M | 35.80M | 28.21M | 21.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |